Name | Oaks Of Clearwater, The |
---|---|
Location | 420 Bay Ave, Clearwater, Florida |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 60 |
Occupancy Rate | 84.33% |
Medicare ID (CCN) | 105323 |
Legal Business Name | Oaks On The Bay Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1497765374 |
Organization Name | BAPTIST ESTATES OF FLORIDA INC |
Doing Business As | OAK BLUFFS HEALTH CENTER |
Address | 420 Bay Ave, Clearwater, FL 33756 |
Phone Number | 727-445-4700 |
News Archive
New research warns that the normalization of 'plus-size' body shapes may be leading to an increasing number of people underestimating their weight - undermining efforts to tackle England's ever-growing obesity problem.
Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA).
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
Almost ten years ago, the group led by Erwin Wagner, currently at the Spanish National Cancer Research Centre (CNIO), developed genetically modified mice showing symptoms very reminiscent to psoriasis.
Australian researchers have used cutting-edge genome technologies to reveal the genetic makeup of a widespread skin parasite causing serious health problems in Aboriginal communities.
› Verified 2 days ago
NPI Number | 1609297654 |
Organization Name | OAKS ON THE BAY, LLC |
Doing Business As | THE OAKS OF CLEARWATER |
Address | 420 Bay Ave, Clearwater, FL 33756 |
Phone Number | 727-445-4700 |
News Archive
New research warns that the normalization of 'plus-size' body shapes may be leading to an increasing number of people underestimating their weight - undermining efforts to tackle England's ever-growing obesity problem.
Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA).
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
Almost ten years ago, the group led by Erwin Wagner, currently at the Spanish National Cancer Research Centre (CNIO), developed genetically modified mice showing symptoms very reminiscent to psoriasis.
Australian researchers have used cutting-edge genome technologies to reveal the genetic makeup of a widespread skin parasite causing serious health problems in Aboriginal communities.
› Verified 2 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
New research warns that the normalization of 'plus-size' body shapes may be leading to an increasing number of people underestimating their weight - undermining efforts to tackle England's ever-growing obesity problem.
Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA).
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
Almost ten years ago, the group led by Erwin Wagner, currently at the Spanish National Cancer Research Centre (CNIO), developed genetically modified mice showing symptoms very reminiscent to psoriasis.
Australian researchers have used cutting-edge genome technologies to reveal the genetic makeup of a widespread skin parasite causing serious health problems in Aboriginal communities.
› Verified 2 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 2 |
Total Amount of Fines in Dollars | $16877 |
Number of Payment Denials | 0 |
Total Number of Penalties | 2 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 23.02 | 14.46 |
Percentage of long-stay residents who lose too much weight | 5.13 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 55.26 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.44 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.24 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 7.75 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.36 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.63 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 10 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 72.91 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 25.47 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.18 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 1.83 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.6 | 95.98 |
Percentage of short-stay residents who made improvements in function | 69.23 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 61.54 | 82.93 |
News Archive
New research warns that the normalization of 'plus-size' body shapes may be leading to an increasing number of people underestimating their weight - undermining efforts to tackle England's ever-growing obesity problem.
Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA).
Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.
Almost ten years ago, the group led by Erwin Wagner, currently at the Spanish National Cancer Research Centre (CNIO), developed genetically modified mice showing symptoms very reminiscent to psoriasis.
Australian researchers have used cutting-edge genome technologies to reveal the genetic makeup of a widespread skin parasite causing serious health problems in Aboriginal communities.
› Verified 2 days ago
Orchid Cove At Clearwater Location: 1980 Sunset Point Rd, Clearwater, Florida 33765 Phone: (727) 443-1588 | |
Kensington Gardens Rehab And Nursing Center Location: 2055 Palmetto St, Clearwater, Florida 33758 Phone: (727) 461-6613 | |
Palm Garden Of Clearwater Location: 3480 Mcmullen Booth Rd, Clearwater, Florida 33761 Phone: (727) 786-6697 |